본문 바로가기
KERD
논문KCI 등재

RNA interference as a novel treatment strategy for chronic hepatitis B infection

Wai-Kay Seto|Man-Fung Yuen|Lung-Yi Mak|Rex Wan-Hin Hui
대한간학회 (The korean Association for the Study of the Liver)|2022.07|Clinical and Molecular Hepatology|제28권 제3호|pp. 408-424|DOI 10.3350/cmh.2022.0012

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

Messenger RNAHepatitis B virusHepatitis B surface antigensSmall-interfering RNAAnti-sense oligonucleotide

초록

Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved clinical outcomes. However, functional cure is rarely attainable by current treatment modalities. RNA interference (RNAi) by small-interfering RNA (siRNA) and anti-sense oligonucleotide (ASO) has been studied as a novel treatment strategy for CHB. RNAi targets post-transcriptional messenger RNAs and pregenomic RNAs to reduce hepatitis B virus (HBV) antigen production and viral replication. By reducing viral antigens, host immune reconstitution against HBV may also be attained. Phase I/II trials on siRNAs have demonstrated them to be safe and well-tolerated. siRNA is effective when given in monthly doses with different total number of doses according to different trial design, and can lead to sustainable dose-dependent mean HBsAg reduction by 2–2.5 log. Incidences of HBsAg seroclearance after siRNA therapy have also been reported. ASOs have also been studied in early phase trials, and a phase Ib study using frequent dosing regimen within 4 weeks could achieve similar HBsAg reduction of 2 log from baseline. Given the established efficacy and safety of nucleos(t) ide analogues (NAs), future RNAi regimens will likely include NA backbone. While the current evidence on RNAi appears promising, it remains undetermined whether the potent HBsAg reduction by RNAi can result in a high rate of HBsAg seroclearance with durability. Data on RNAi from phase IIb/III trials are keenly anticipated.

Abstract

Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved clinical outcomes. However, functional cure is rarely attainable by current treatment modalities. RNA interference (RNAi) by small-interfering RNA (siRNA) and anti-sense oligonucleotide (ASO) has been studied as a novel treatment strategy for CHB. RNAi targets post-transcriptional messenger RNAs and pregenomic RNAs to reduce hepatitis B virus (HBV) antigen production and viral replication. By reducing viral antigens, host immune reconstitution against HBV may also be attained. Phase I/II trials on siRNAs have demonstrated them to be safe and well-tolerated. siRNA is effective when given in monthly doses with different total number of doses according to different trial design, and can lead to sustainable dose-dependent mean HBsAg reduction by 2–2.5 log. Incidences of HBsAg seroclearance after siRNA therapy have also been reported. ASOs have also been studied in early phase trials, and a phase Ib study using frequent dosing regimen within 4 weeks could achieve similar HBsAg reduction of 2 log from baseline. Given the established efficacy and safety of nucleos(t) ide analogues (NAs), future RNAi regimens will likely include NA backbone. While the current evidence on RNAi appears promising, it remains undetermined whether the potent HBsAg reduction by RNAi can result in a high rate of HBsAg seroclearance with durability. Data on RNAi from phase IIb/III trials are keenly anticipated.

참고문헌 (99)

  1. Polaris Observatory Collaborators, "Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016 : a modelling study", Lancet Gastroenterol Hepatol, 3, pp.383~403 (2018)
  2. Seto WK, "Chronic hepatitis B virus infection", Lancet, 392, pp.2313~2324 (2018)
  3. Mak LY, "Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval", J Viral Hepat, 26, pp.818~827 (2019)
  4. Yuen MF, "HBsAg seroclearance in chronic hepatitis B in Asian patients : replicative level and risk of hepatocellular carcinoma", Gastroenterology, 135, pp.1192~1199 (2008)
  5. Mak LY, "Novel antivirals in clinical development for chronic hepatitis B infection", Viruses, 13, pp.1169~ (2021)
  6. Blank A, "First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B", J Hepatol, 65, pp.483~489 (2016)
  7. Squires KE, "ATI-2173, a novel liver-targeted non-chainterminating nucleotide for hepatitis B virus cure regimens", Antimicrob Agents Chemother, 64, pp.e00836~ (2020)[DOI]
  8. Morrissey DV, "Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs", Nat Biotechnol, 23, pp.1002~1007 (2005)
  9. Hui RWH, "Role of core", capsid inhibitors in functional cure strategies for chronic hepatitis B, 2020, pp.19, 293~301
  10. Real CI, "Nucleic acid-based polymers effective against hepatitis B virus infection in patients don’t harbor immunostimulatory properties in primary isolated liver cells", Sci Rep, 7, pp.43838~ (2017)
  11. Kao CC, "Mechanism of action of hepatitis B virus S antigen transportinhibiting oligonucleotide polymer, STOPS, molecules", Mol Ther Nucleic Acids, 27, pp.335~348 (2021)
  12. Erken R, "Farnesoid X receptor agonist for the treatment of chronic hepatitis B : a safety study", J Viral Hepat, 28, pp.1690~1698 (2021)
  13. Boni C, "TLR7 agonist increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(t)ide analogues", Gastroenterology, 154, pp.1764~1777 (2018)
  14. Gane E, "Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B : a pilot study", J Hepatol, 71, pp.900~907 (2019)
  15. Fergusson JR, "Immune-mobilizing monoclonal T cell receptors mediate specific and rapid elimination of hepatitis B-infected cells", Hepatology, 72, pp.1528~1540 (2020)
  16. Boni C, "Combined GS-4774 and tenofovir therapy can improve HBVspecific T-cell responses in patients with chronic hepatitis", Gastroenterology, 157, pp.227~241 (2019)
  17. Lee HW, "A prospective, openlabel, dose-escalation, single-center, phase 1 study for GC1102, a recombinant human immunoglobulin for chronic hepatitis B patients", Hepatology, 68(S1), pp.453~ (2018)
  18. Yeo YH, "Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection : a systematic review and meta-analysis", Gastroenterology, 156, pp.635~646 (2019)
  19. Fire A, "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans", Nature, 391, pp.806~811 (1998)
  20. MacRae IJ, "In vitro reconstitution of the human RISC-loading complex", Proc Natl Acad Sci U S A, 105, pp.512~517 (2008)
  21. Caplen NJ, "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems", Proc Natl Acad Sci U S A, 98, pp.9742~9747 (2001)
  22. Rivas FV, "Purified argonaute2 and an siRNA form recombinant human RISC", Nat Struct Mol Biol, 12, pp.340~349 (2005)
  23. Iwasaki S, "Drosophila argonaute1 and argonaute2employ distinct mechanisms for translational repression", Mol Cell, 34, pp.58~67 (2009)
  24. Petersen CP, "Short RNAs repress translation after initiation in mammalian cells", Mol Cell, 21, pp.533~542 (2006)
  25. Verdel A, "RNAi-mediated targeting of heterochromatin by the RITS complex", Science, 303, pp.672~676 (2004)
  26. Haley B, "Kinetic analysis of the RNAi enzyme complex", Nat Struct Mol Biol, 11, pp.599~606 (2004)
  27. Adams D, "Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis", N Engl J Med, 379, pp.11~21 (2018)
  28. Setten RL, "The current state and future directions of RNAi-based therapeutics", Nat Rev Drug Discov, 18, pp.421~446 (2019)
  29. Jacque JM, "Modulation of HIV-1 replication by RNA interference", Nature, 418, pp.435~438 (2002)
  30. Kumar P, "T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice", Cell, 134, pp.577~586 (2008)
  31. Bitko V, "Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses", BMC Microbiol, 1, pp.34~ (2001)
  32. Gitlin L, "Poliovirus escape from RNA interference : short interfering RNA-target recognition and implications for therapeutic approaches", J Virol, 79, pp.1027~1035 (2005)
  33. Geisbert TW, "Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference : a proof-ofconcept study", Lancet, 375, pp.1896~1905 (2010)
  34. Levanova A, "RNA interference as a prospective tool for the control of human viral infections", Front Microbiol, 9, pp.2151~ (2018)
  35. Jackson AL, "Recognizing and avoiding siRNA offtarget effects for target identification and therapeutic application", Nat Rev Drug Discov, 9, pp.57~67 (2010)
  36. Qiu S, "A computational study of off-target effects of RNA interference", Nucleic Acids Res, 33, pp.1834~1847 (2005)
  37. Naito Y, "siRNA design software for a target genespecific RNA interference", Front Genet, 3, pp.102~ (2012)
  38. Hickerson RP, "Stability study of unmodified siRNA and relevance to clinical use", Oligonucleotides, 18, pp.345~354 (2008)
  39. Liao H, "Biomembrane-permeable and ribonucleaseresistant siRNA with enhanced activity", Oligonucleotides, 15, pp.196~205 (2005)
  40. Sledz CA, "Activation of the interferon system by short-interfering RNAs", Nat Cell Biol, 5, pp.834~839 (2003)
  41. Alexopoulou L, "Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3", Nature, 413, pp.732~738 (2001)
  42. Czauderna F, "Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells", Nucleic Acids Res, 31, pp.2705~2716 (2003)
  43. Jackson AL, "Position-specific chemical modification of siRNAs reduces"off-target"transcript silencing", RNA, 12, pp.1197~1205 (2006)
  44. Judge AD, "Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo", Mol Ther, 13, pp.494~505 (2006)
  45. Allerson CR, "Fully 2’-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA", J Med Chem, 48, pp.901~904 (2005)
  46. Shen C, "Adenovirus-delivered siRNA", Methods Mol Biol, 252, pp.523~532 (2004)
  47. Kaczmarek JC, "Advances in the delivery of RNA therapeutics : from concept to clinical reality", Genome Med, 9, pp.60~ (2017)
  48. Springer AD, "GalNAc-siRNA conjugates : leading the way for delivery of RNAi therapeutics", Nucleic Acid Ther, 28, pp.109~118 (2018)
  49. Konishi M, "Inhibition of HBV replication by siRNA in a stable HBV-producing cell line", Hepatology, 38, pp.842~850 (2003)
  50. Boden D, "Human immunodeficiency virus type 1 escape from RNA interference", J Virol, 77, pp.11531~11535 (2003)
  51. Kapadia SB, "Interference of hepatitis C virus RNA replication by short interfering RNAs", Proc Natl Acad Sci U S A, 100, pp.2014~2018 (2003)
  52. Buti M, "Hepatitis B virus genome variability and disease progression : the impact of precore mutants and HBV genotypes", J Clin Virol (2005)
  53. Wu HL, "RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant", Gastroenterology, 128, pp.708~716 (2005)
  54. Shih YM, "Combinatorial RNA interference therapy prevents selection of preexisting HBV variants in human liver chimeric mice", Sci Rep, 5, pp.15259~ (2015)
  55. Kayesh MEH, "Toll-like receptor response to hepatitis B virus infection and potential of TLR agonists as immunomodulators for treating chronic hepatitis B : an overview", Int J Mol Sci, 22, pp.10462~ (2021)
  56. Fisicaro P, "Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B", Gastroenterology, 138, pp.682~693 (2010)[DOI]
  57. Stoop JN, "Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection", Hepatology, 41, pp.771~778 (2005)
  58. Le Bert N, "Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection", Gastroenterology, 159, pp.652~664 (2020)
  59. Park JJ, "Hepatitis B virus--specific and global T-cell dysfunction in chronic hepatitis B", Gastroenterology, 150, pp.684~695 (2016)
  60. Seto WK, "Hepatitis B surface antigen seroclearance during nucleoside analogue therapy : surface antigen kinetics, outcomes, and durability", J Gastroenterol, 51, pp.487~495 (2016)
  61. Boni C, "Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues", Gastroenterology, 143, pp.963~973 (2012)
  62. Sohail M, "Antisense oligonucleotides selected by hybridisation to scanning arrays are effective reagents in vivo", Nucleic Acids Res, 29, pp.2041~2051 (2001)
  63. Dhuri K, "Antisense oligonucleotides : an emerging area in drug discovery and development", J Clin Med, 9, pp.2004~ (2020)
  64. Miller CM, "Receptor-mediated uptake of phosphorothioate antisense oligonucleotides in different cell types of the liver", Nucleic Acid Ther, 28, pp.119~127 (2018)
  65. Dominska M, "Breaking down the barriers : siRNA delivery and endosome escape", J Cell Sci, 123(Pt 8), pp.1183~1189 (2010)
  66. Vocelle D, "Endocytosis controls siRNA efficiency : implications for siRNA delivery vehicle design and cellspecific targeting", Nucleic Acid Ther, 30, pp.22~32 (2020)
  67. Linnane E, "Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines", Nucleic Acids Res, 47, pp.4375~4392 (2019)
  68. Gane E, "Clinical study of single-stranded oligonucleotide RO7062931 in healthy volunteers and patients with chronic hepatitis B", Hepatology, 74, pp.1795~1808 (2021)
  69. Liang XH, "RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus", Mol Ther, 25, pp.2075~2092 (2017)
  70. Liang XH, "Antisense oligonucleotides targeting translation inhibitory elements in 5’ UTRs can selectively increase protein levels", Nucleic Acids Res, 45, pp.9528~9546 (2017)
  71. Tallet-Lopez B, "Antisense oligonucleotides targeted to the domain IIId of the hepatitis C virus IRES compete with 40S ribosomal subunit binding and prevent in vitro translation", Nucleic Acids Res, 31, pp.734~742 (2003)
  72. Goodarzi G, "Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen", J Gen Virol, 71(Pt 12), pp.3021~3025 (1990)
  73. Wooddell CI, "Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection", Mol Ther, 21, pp.973~985 (2013)
  74. Wooddell CI, "RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg", Sci Transl Med (2017)
  75. Gane E, "Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection : week 48 follow-up results", J Hepatol, 75, pp.S287~S288 (2021)
  76. Sterinu-Cercel A, "A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg-positive and-negative virally suppressed subjects with hepatitis B", J Hepatol, 66, pp.S688~S689 (2017)
  77. Gane E, "Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors", J Hepatol (2021)
  78. Thi EP, "ARB-1740, a RNA interference therapeutic for chronic hepatitis B infection", ACS Infect Dis, 5, pp.725~737 (2019)
  79. Wooddell C, "Development of subcutaneously administered RNAi therapeutic ARO-HBV for chronic hepatitis B virus infection", J Hepatol, 68, pp.S18~S19 (2018)
  80. Durantel D, "New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus", J Hepatol (2016)
  81. Schluep T, "Safety, tolerability, and pharmacokinetics of ARC-520 injection, an RNA interference-based therapeutic for the treatment of chronic hepatitis B virus infection, in healthy volunteers", Clin Pharmacol Drug Dev, 6, pp.350~362 (2017)
  82. Yuen MF, "RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection", Hepatology, 72, pp.19~31 (2020)
  83. Yuen MF, "Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment", Gut, 71, pp.789~797 (2022)
  84. Bi-weekly dosing of ARB-1467 LNP siRNA in HBeAgNegative, virally suppressed patients with chronic HBV infection leads to deeper declines in HBsAg and potential association with IL28b, "Agarwal K", AASLD The Liver Meeting 2017, ~ (2017)
  85. "Arbutus reports fourth quarter and yearend 2018 financial results and describes recent clinical accomplishments and key 2019 objectives"[URL]
  86. Low HBsAg levels maintained following cessation of the GalNAc-siRNA, AB-729, in chronic hepatitis B patients on nucleos(t)ide analogue therapy, "Yuen MF", AASLD The Liver Meeting, ~ (2021)
  87. Thi EP, "Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms and HBV RNA", J Hepatol, 75, pp.S760~ (2021)
  88. Paratala BS, "Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T cell activation markers", J Hepatol, 75, pp.S761~ (2021)
  89. HBV RNAi inhibitor RG6346 in Phase 1b-2a trial was safe, well tolerated, and resulted in substantial and durable reductions in serum HBsAg levels, "Yuen MF", AASLD The Liver Meeting, ~ (2020)
  90. Incorporation of novel siRNA chemistries significantly improves the potency and durability of HBV siRNAs in the AAV-HBV mouse model, "Hong J", AASLD The Liver Meeting, ~ (2021)
  91. Hong J, "ALG-125755, a small interfering RNA(siRNA)against hepatitis B virus(HBV)effectively inhibits hepatitis B surface antigen(HBsAg)secretion in HBV cell models and the AAV-HBV mouse model", J Hepatol, 75, pp.S742~ (2021)
  92. "Aligos Therapeutics to present phase 1safety and pharmacokinetic data for STOPS™ molecule drug candidate ALG-010133 and several nonclinical chronic hepatitis B programs at the european association for the study of the Liver’s Digital International Liver Congress 2021"[URL]
  93. Results after 12 weeks treatment of multiple doses of GSK3389404in chronic hepatitis B (CHB) subjects on stable nucleos(t)ide therapy in a phase 2a double-blind, placebo-controlled study, "Yuen MF", AASLD The Liver Meeting, ~ (2019)
  94. Yuen MF, "Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial", Nat Med, 27, pp.1725~1734 (2021)
  95. Preliminary results from a phase 2 study evaluating VIR-2218alone and in combination with pegylated interferon Alfa-2a in participants with chronic hepatitis B infection, "Yuen MF", AASLD The Liver Meeting, ~ (2021)
  96. Efficacy and safety of the siRNA JNJ-3989 and, "or the capsid assembly modulator JNJ-6379 for the treatment of chronic hepatitis B virus infection : results from the phase 2b REEF-1 study", Yuen MF, 2021
  97. Tan H, "Combination drug interactions of hepatitis B virus(HBV)small interfering RNA(siRNA)and antisense oligonucleotides(ASO)in vitro and in vivo", J Hepatol, 75, pp.S720~ (2021)
  98. Triple combination of anti-hepatitis B virus drugs demonstrates synergistic activity in vitro, "Tan H", AASLD The Liver Meeting, ~ (2021)
  99. Michler T, "Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice", Gastroenterology, 158, pp.1762~1775 (2020)

관련 논문AI추천

Prospect of emerging treatments for hepatitis B virus functional cureJames Fung, Lung-Yi Mak, Man-Fung Yuen, Rex Wan-Hin Hui, Wai-Kay Seto대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Targeting the innate immune system in treating hepatitis B: prospects for functional cureKaren Cheuk-Ying Ho, Lung-Yi Mak, Man-Fung Yuen, Rex Wan-Hin Hui, Wai-Kay Seto대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Toward a Functional Cure for Hepatitis BRay Gautam거트앤리버 소화기연관학회협의회 · Gut and Liver2024 · 제18권 제4호Global strategies and actions to eliminate hepatitis B virus infectionChih-Lin Lin, Jia-Horng Kao대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제4호Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus이민종, Jun Sik Yoon, Sun Woong Kim, Yuri Cho대한간학회 · Clinical and Molecular Hepatology2022 · 제28권 제1호The role of different viral biomarkers on the management of chronic hepatitis BJames Fung, Lung-Yi Mak, Man-Fung Yuen, Rex Wan-Hin Hui, Wai Kay Seto대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호

이 간행물의 다른 논문 (18건)

Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma성필수pp. 333-350The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infectionYoung-Joo Jin, 조순구, Jung Hwan Yu, Jin-Woo Leepp. 351-361Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound이정민, Jeong Hee Yoon, Tae-Hyung Kim, Junghoan Parkpp. 362-379Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?Dong Hyun Sinn, Myung Ji Gohpp. 380-395Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevanceMina Komutapp. 396-407
원문 보기